JP2023548945A5 - - Google Patents

Info

Publication number
JP2023548945A5
JP2023548945A5 JP2023528750A JP2023528750A JP2023548945A5 JP 2023548945 A5 JP2023548945 A5 JP 2023548945A5 JP 2023528750 A JP2023528750 A JP 2023528750A JP 2023528750 A JP2023528750 A JP 2023528750A JP 2023548945 A5 JP2023548945 A5 JP 2023548945A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
polypeptide
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548945A (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/129067 external-priority patent/WO2022099695A1/en
Application filed filed Critical
Publication of JP2023548945A publication Critical patent/JP2023548945A/ja
Publication of JP2023548945A5 publication Critical patent/JP2023548945A5/ja
Pending legal-status Critical Current

Links

JP2023528750A 2020-11-16 2021-11-08 Cd164融合タンパク質およびその適用 Pending JP2023548945A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/129067 2020-11-16
PCT/CN2020/129067 WO2022099695A1 (en) 2020-11-16 2020-11-16 Cd164 fusion and uses thereof
PCT/CN2021/129378 WO2022100555A1 (en) 2020-11-16 2021-11-08 Cd164 fusion and uses thereof

Publications (2)

Publication Number Publication Date
JP2023548945A JP2023548945A (ja) 2023-11-21
JP2023548945A5 true JP2023548945A5 (https=) 2024-09-19

Family

ID=81600756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528750A Pending JP2023548945A (ja) 2020-11-16 2021-11-08 Cd164融合タンパク質およびその適用

Country Status (5)

Country Link
US (1) US20240002469A1 (https=)
EP (1) EP4244260A4 (https=)
JP (1) JP2023548945A (https=)
CN (4) CN115947871A (https=)
WO (2) WO2022099695A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099695A1 (en) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Cd164 fusion and uses thereof
CN116609531B (zh) * 2023-05-23 2025-10-31 哈尔滨医科大学 Mydgf在治疗血管内模增生的制药和医疗器械中的应用
WO2025047991A1 (en) * 2023-09-01 2025-03-06 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing a liver disorder
CN119798458B (zh) * 2024-12-05 2025-09-26 河南大学 一种dr5和mydgf的融合蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045074A1 (es) * 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
US7803910B2 (en) * 2005-01-24 2010-09-28 Merck Serono S.A. Soluble CD164 polypeptides
US9156897B2 (en) * 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2014106839A1 (en) * 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
WO2015200357A2 (en) * 2014-06-23 2015-12-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
CN114805532A (zh) * 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
IL270024B2 (en) * 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
CN111544572B (zh) * 2020-05-15 2022-06-07 中山大学 Mydgf蛋白在制备端粒酶表达和细胞衰老调控剂中的应用
WO2022099695A1 (en) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Cd164 fusion and uses thereof

Similar Documents

Publication Publication Date Title
JP2023548945A5 (https=)
KR102927838B1 (ko) 이중 작용 단백질 및 이를 포함하는 약학적 조성물
US11858975B2 (en) Multi-domain active protein for treating metabolic diseases
JP6412183B2 (ja) 作用持続時間が増した改変ポリペプチド
JP5373855B2 (ja) 選択可能な特性を有するハイブリッドポリペプチド
JP2025114622A (ja) 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物
CN105008395B (zh) 长效单链胰岛素类似物
KR20170049319A (ko) 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10815286B2 (en) Fusion protein for treating intestinal diseases
CN115003702A (zh) Cd164融合蛋白及其应用
JP2009504681A (ja) 選択可能な特性を有するハイブリッドポリペプチド
WO2023280133A1 (zh) 融合蛋白及其应用
CN118076373A (zh) 用于联合疗法的包括生长分化因子-15变体和胰高血糖素样肽-1受体激动剂的组合物
CN111234015B (zh) 用于延长药物半衰期的抗体、其融合蛋白和应用
JP2023509189A5 (https=)
JP5264725B2 (ja) ペプチド性薬物の粘膜吸収促進剤を含有する粘膜投与用組成物、及びその投与方法
RU2795548C2 (ru) Фармацевтическая композиция для предотвращения или лечения гепатита, фиброза печени и цирроза печени, включающая слитые белки
HK40091844A (zh) 双功能蛋白质和包含其的药物组合物
HK40086042A (zh) 双功能蛋白质和包含其的药物组合物
HK40012348B (zh) 用於预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物
RU2024106867A (ru) Аффимеры, связывающиеся с неонатальным Fc рецептором
RU2023111124A (ru) Фармацевтическая композиция для предотвращения или лечения гепатита, фиброза печени и цирроза печени, включающая слитые белки
HK40012348A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins